Eisenmenger’s syndrome diagnostic study of choice
|
Eisenmenger’s syndrome Microchapters |
|
Diagnosis |
|---|
|
Eisenmenger’s syndrome ACC/AHA Guidelines for Evaluation of Patients |
|
Treatment |
|
Eisenmenger’s syndrome diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Eisenmenger’s syndrome diagnostic study of choice |
|
Eisenmenger’s syndrome diagnostic study of choice in the news |
|
Risk calculators and risk factors for Eisenmenger’s syndrome diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Abdelrahman Ibrahim Abushouk, MD[2], Priyamavada Singh, MBBS [3], Kristin Feeney, B.S. [4]
Overview
2018 ACC/AHA Guidelines for the Management of Adults With Congenital Heart Disease (DO NOT EDIT)[1]
| Class I |
| "1. Care of adult patients with CHD-related PAH should be performed in centers that have shared expertise and training in both ACHD and PAH. (Level of Evidence: C)" |
| "2. The evaluation of all ACHD patients with suspected PAH should include noninvasive assessment of cardiovascular anatomy and potential shunting, as detailed below:" |
| "a. Pulse oximetry, with and without administration of supplemental oxygen, as appropriate. (Level of Evidence: C)" |
| "b. Chest x-ray. (Level of Evidence: C)" |
| "c. ECG. (Level of Evidence: C)" |
| "d. Diagnostic cardiovascular imaging via TTE, TEE, MRI, or CT as appropriate. (Level of Evidence: C)" |
| "e. Complete blood count and nuclear lung scintigraphy. (Level of Evidence: C)" |
| "3. If PAH is identified but its causes are not fully recognized, additional testing should include the following:" |
| "a. Pulmonary function tests with volumes and diffusion capacity (diffusing capacity of the lung for carbon monoxide). (Level of Evidence: C)" |
| "b. Pulmonary embolism-protocol CT with parenchymal lung windows. (Level of Evidence: C)" |
| "c. Additional testing as appropriate to rule out contributing causes of PAH. (Level of Evidence: C)" |
| "d. Cardiac catheterization at least once, with potential for vasodilator testing or anatomic intervention, at a center with expertise in catheterization, PAH, and management of CHD-PAH. (Level of Evidence: C)" |
| Class IIa |
| "1. It is reasonable to include a 6-minute walk test or similar nonmaximal cardiopulmonary exercise test as part of the functional assessment of patients with CHD-PAH. (Level of Evidence: C)" |
References
- ↑ Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM et al. (2019) 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139 (14):e698-e800. DOI:10.1161/CIR.0000000000000603 PMID: 30586767